**Core Concept**
Vascular lesions in the liver can be caused by various factors, including certain medications and toxins that induce vascular injury or obstruction. This phenomenon is often associated with the development of peliosis hepatis, a condition characterized by the presence of blood-filled cystic spaces within the liver parenchyma.

**Why the Correct Answer is Right**
The correct answer is associated with the inhibition of vascular endothelial growth factor (VEGF) signaling pathway. This pathway is crucial for the regulation of angiogenesis, the process of new blood vessel formation. Inhibition of VEGF signaling can lead to vascular injury and obstruction, resulting in the formation of vascular lesions in the liver. The correct answer is associated with the use of a specific class of medications that target the VEGF pathway.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not directly associated with the inhibition of vascular endothelial growth factor (VEGF) signaling pathway. While it may have some effects on the liver, it is not the primary cause of vascular lesions in this organ.

**Option B:** This option is incorrect because it is not commonly associated with the development of vascular lesions in the liver. It may have other toxic effects on the liver, but it is not the primary cause of vascular lesions.

**Option C:** This option is incorrect because it is not directly associated with the inhibition of vascular endothelial growth factor (VEGF) signaling pathway. While it may have some effects on the liver, it is not the primary cause of vascular lesions in this organ.

**Option D:** This option is incorrect because it is not commonly associated with the development of vascular lesions in the liver. It may have other toxic effects on the liver, but it is not the primary cause of vascular lesions.

**Clinical Pearl / High-Yield Fact**
It is essential to recognize that medications that inhibit the VEGF signaling pathway can cause vascular lesions in the liver. This is particularly important in patients with pre-existing liver disease or those taking multiple medications that may interact with the VEGF pathway.

**Correct Answer:** C. Bevacizumab, a monoclonal antibody that targets VEGF, is known to cause vascular lesions in the liver.